Imported from USA
From the Back Cover
New technologies and tools to guide drugs through the discovery process
Most drugs never leave the laboratory as a result of failure to predict efficacy and safety. In response, this book
offers readers an array of new and emerging technologies. These technologies arm pharmaceutical scientists with more
systematic and effective approaches for deciphering the complex interactions among chemistry, biology, and medicine,
helping to ensure that more research efforts focus on drugs that can be successfully translated from the laboratory to
the clinic and onto the market. Among the topics addressed in Drug Efficacy, Safety, and Biologics Discovery are:
* High throughput protein-based technologies and computational models for drug development, efficacy, toxicity, systems
pharmacology, biomarkers, biomolecular networks, computational systems biology modeling of dosimetry, cellular response
pathways, nanotechnology to improve drug delivery, and modeling efficacy and safety of engineered biologics
Each of the fourteen chapters has been authored by one or more of the leading experts in the field. Their advice is not
only based on a thorough review of the latest findings, but also their own firsthand experience in drug discovery and
development. Extensive references guide readers to the literature for more in-depth investigations of particular topics.
By cutting across the many disciplines needed for successful drug discovery, this book suits the needs of all chemists,
biologists, and technologists involved in drug discovery and development. Moreover, by advocating for cross-disciplinary
collaboration, this book is certain to fuel future innovation in drug discovery.
About the Author
Sean Ekins, MSc, PHD, DSc, is the Principal at Collaborations in Chemistry; and Adjunct Associate Professor in the
Department of Pharmaceutical Sciences at the University of Maryland, School of Pharmacy. Dr. Ekins has published widely
on ADME/Tox, systems biology, computational, and in vitro drug discovery approaches. He has previously edited two Wiley
books: Computer Applications in Pharmaceutical Research and Development (2006) and Computational Toxicology: Risk
Assessment for Pharmaceutical and Environmental Chemicals (2007).
Jinghai J. Xu, PHD, is Director of Automated Biotechnology at Merck. Previously he headed predictive toxicology at
Pfizer, where he led research activities in drug-induced liver injury, genetic toxicology, drug transporters, assay
development, high content screening, in vitro in vivo correlations, systems biology, and systems toxicology. Dr. Xu has
served on steering committees of academic-industry and industry-industry collaborations, and as a guest lecturer at the
Massachusetts Institute of Technology.